Bank of America Corp DE lifted its position in Mesoblast Limited (NASDAQ:MESO - Free Report) by 1,503.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 290,728 shares of the company's stock after purchasing an additional 272,595 shares during the quarter. Bank of America Corp DE owned 0.23% of Mesoblast worth $5,756,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Strategic Financial Concepts LLC bought a new stake in shares of Mesoblast in the 4th quarter valued at about $2,744,000. Quadrant Capital Group LLC lifted its stake in shares of Mesoblast by 41.1% in the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after acquiring an additional 1,891 shares during the last quarter. LPL Financial LLC lifted its stake in shares of Mesoblast by 7.7% in the 4th quarter. LPL Financial LLC now owns 38,882 shares of the company's stock valued at $770,000 after acquiring an additional 2,795 shares during the last quarter. Barclays PLC bought a new stake in shares of Mesoblast in the 4th quarter valued at about $38,000. Finally, Oaktree Fund Advisors LLC bought a new stake in shares of Mesoblast in the 4th quarter valued at about $949,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.
Mesoblast Price Performance
MESO traded down $0.07 during midday trading on Friday, reaching $10.61. 176,506 shares of the company's stock traded hands, compared to its average volume of 270,365. The firm has a fifty day moving average of $11.26 and a two-hundred day moving average of $13.99. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast Limited has a 52 week low of $5.78 and a 52 week high of $22.00.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Mesoblast has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Research Report on Mesoblast
Mesoblast Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
